Fig. 1 · Structure

Documents & Downloads

Lapatinib Ditosylate

Cat. No. A10514 CAS 388082-77-7

HER2 inhibitor

Lapatinib is a dual tyrosine kinase inhibitor which interrupts the HER2 growth receptor pathway.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
ErbB2 IC50 9.2nM
EGFR IC50 10.8nM
ErbB4 IC50 367nM
c-Src IC50 3.5μM
C-Raf-1 IC50 >10μM
MEK IC50 >10μM
ERK IC50 >10μM
c-Fms IC50 >10μM
CDK1 IC50 >10μM
CDK2 IC50 >10μM
p38 IC50 >10μM
Tie-2 IC50 >10μM
VEGFR2 IC50 >10μM

13 targets · Scroll to view more

Cellular Effect

Cell Line Activity Value Description Reference
A-431 IC50 1.69 μM Cytotoxicity against human A431 cells over expressing EGFR assessed as reduction in cell viability after 72 hrs by sulforhodamine B assay [PMID: 29902719]
MDA-MB-361 IC50 13.73 μM Cytotoxicity against human MDA-MB-361 cells over expressing HER2 assessed as reduction in cell viability after 72 hrs by sulforhodamine B assay [PMID: 29902719]
NCI-H1975 IC50 11.46 μM Cytotoxicity against human NCI-H1975 cells harboring EGFR T790M mutant assessed as reduction in cell viability after 72 hrs by sulforhodamine B assay [PMID: 29902719]
SK-BR-3 IC50 0.17 μM Cytotoxicity against human SKBR3 cells over expressing HER2 assessed as reduction in cell viability after 72 hrs by sulforhodamine B assay [PMID: 29902719]

Lapatinib Ditosylate Research Summary

This section summarizes 1 in vitro study of Lapatinib Ditosylate from 1 published reference.

Lapatinib Ditosylate In Vitro Studies

In DFTD T1 tumour cells, lapatinib explicitly sourced as Adooq A10514 reduced STAT3 phosphorylation in immunoblots assessed after 6 and 24 hours at 1 µM. DMSO, total STAT3 and HSC70 controls were shown. This cellular signaling result does not establish direct inhibition of STAT3. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

STAT3 phosphorylation response to A10514 in DFTD T1 cells

Cell-based study · Tasmanian devil facial tumour disease T1 cells, with devil fibroblasts shown as a comparator in Figure 3I. [1]

Lapatinib treatment was associated with reduced STAT3 phosphorylation in T1 cells. The panel shows DMSO controls, total STAT3 and HSC70 loading controls at 6 and 24 hours; sapitinib was tested separately. This is a cellular signaling observation consistent with ERBB-linked signaling, not evidence that STAT3 is a direct biochemical target of lapatinib. No numerical effect size or IC50 was inferred from the immunoblots.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
STAT3 Y705 and S727 phosphorylation in T1 cellsQualitative phosphorylation response Reduced phosphorylation relative to DMSO controls (qualitative immunoblots).[1]

Literature-Reported Treatment Conditions

Treatment concentration
1 µM lapatinib
Exposure duration
6 h and 24 h (Figure 3I labels)
Method
Cell treatment followed by immunoblotting.
Vehicle
DMSO; DMSO-treated controls shown. Final DMSO percentage for this panel not specified.
Reported limits
Figure 3I does not give a panel-specific biological replicate count or quantitative effect size. The general quantification method mentions three independent blots per quantification; this is not assigned as n for the unquantified panel I.
Methods and source locations

Compound reported in the paper: Lapatinib; Compound label in the paper: Adooq Bioscience Cat#A10514

Directly documented use of A10514 in this cellular experiment; no claim of current-lot validation or general efficacy in other tumours.

Figure 3I (#fig3), directly viewed image and caption; STAR Methods: Key Resources Table, inhibitor-material paragraph and Western Blotting; Results, Molecular Dissection of ERBB-STAT3 Axis in DFTD

STAT3 Y705 and S727 phosphorylation in T1 cells: Western blotting with phospho-Y705 STAT3 and phospho-S727 STAT3 antibodies, total STAT3 and HSC70 controls; 6 h and 24 h panels. — Figure 3I (#fig3), directly viewed image and caption; STAR Methods: Key Resources Table, inhibitor-material paragraph and Western Blotting

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 388082-77-7
Applications HER2 inhibitor
Formula C43H42ClFN4O10S3
Molecular Weight 925.46
SMILES
CC1=CC=C(C=C1)S(=O)(=O)O.CC1=CC=C(C=C1)S(=O)(=O)O.CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 93 mg/mL (100.49 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
9 mg/mL
Vehicle
2% DMSO+30% PEG 300+ddH2O

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Lapatinib Ditosylate Research References

  1. [1] Kosack L, Wingelhofer B, Popa A, et al. The ERBB-STAT3 Axis Drives Tasmanian Devil Facial Tumor Disease Cancer cell (2019). PMID: 30645971 DOI: 10.1016/j.ccell.2018.11.018 Source material

Added to your cart

View Cart Checkout
Loading...